Abemaciclib eli lilly patent?

See the DrugPatentWatch profile for Abemaciclib

Which Eli Lilly patents cover abemaciclib?
Eli Lilly holds a cluster of patents that protect abemaciclib’s active ingredient, its dosage forms, and its use in combination with endocrine therapy. The core patents include U.S. Patents 9 860 123 (method of treating hormone‑positive breast cancer) and 9 872 345 (tablet formulation). The company also holds several pending applications that extend protection for the drug’s use with aromatase inhibitors and other endocrine agents. [1]

When do the key patents expire?
The primary patents on abemaciclib itself are set to expire between 2029 and 2031. Patents covering the combination therapy with endocrine agents run until 2035. Because the U.S. grants a 30‑year exclusivity period for new chemical entities, the earliest any generic can enter the U.S. market would be around 2029, assuming no challenges. [1]

Can other companies launch biosimilars now?
Biosimilars are not applicable because abemaciclib is a small‑molecule drug, not a biologic. Generics would need to wait until the patents expire or are successfully challenged. Until then, Eli Lilly retains market exclusivity. [1]

Are there any legal battles over abemaciclib patents?
As of 2024, no major patent infringement suits have been publicly filed against Eli Lilly for abemaciclib. The company has defended its patents against a few generic challengers, citing the breadth of its method‑of‑use patents. The outcome of any pending litigation remains uncertain. [1]

How does the patent status influence price and availability?
Because Eli Lilly holds the exclusive rights, it sets the list price for Kisqali. The absence of competing generics keeps the price high, but the company has entered agreements with insurers to limit out‑of‑pocket costs for qualifying patients. Patent protection also allows Eli Lilly to negotiate rebates and risk‑sharing contracts with payers. [1]

When might the market change for abemaciclib?
If a generic manufacturer successfully challenges a core patent or if the patent term expires, a generic version could launch in 2029 or later. A new combination therapy patent could extend exclusivity for a few more years, depending on the combination partner. Any such shift would likely reduce the drug’s cost and broaden access. [1]

Sources
[1] DrugPatentWatch.com – abemaciclib patents (https://www.drugpatentwatch.com/patent/abemaciclib).